INBX (Inhibrx Biosciences) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Days Payable?

Inhibrx Biosciences's average Accounts Payable for the three months ended in Dec. 2024 was $10.81 Mil. Inhibrx Biosciences's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Inhibrx Biosciences's Days Payable or its related term are showing as below:

INBX's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 122.35
* Ranked among companies with meaningful Days Payable only.

Inhibrx Biosciences's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Inhibrx Biosciences Days Payable Historical Data

The historical data trend for Inhibrx Biosciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Days Payable Chart

Inhibrx Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

Days Payable

Inhibrx Biosciences Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Inhibrx Biosciences's Days Payable

For the Biotechnology subindustry, Inhibrx Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibrx Biosciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's Days Payable falls into.

Inhibrx Biosciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Inhibrx Biosciences's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (10.954	+	9.245)	/	2 )	/	0	*	365
=	10.0995					/	0	*	365
=	N/A

Inhibrx Biosciences's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (12.37	+	9.245)	/	2 )	/	0	*	365 / 4
=	10.8075					/	0	*	365 / 4
=	N/A

Inhibrx Biosciences Days Payable Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.